No Result

View All Result

No products in the cart.

Home StudyGraphics

#VisualAbstract: Rituximab plus lenalidomide shows comparable survival compared to chemotherapy for CD20⁺ follicular lymphoma

byTeddy Guo

October 19, 2022

in StudyGraphics

Reading Time: 1 min read

#VisualAbstract: Pembrolizumab provides survival benefit in PD-L1 positive advanced head and neck cancer

RelatedReports

Surgical site anesthetic infusion may enhance analgesia after mastectomy

Rheumatology

Rituximab may not be superior to standard treatment in inducing remission in eosinophilic granulomatosis with polyangiitis

August 2, 2025

Chemotherapy and stem-cell transplant for multiple myeloma remain superior

Hematology

CAR+ T-cell lymphoma linked to cilta-cel therapy in myeloma

March 7, 2025

No clinical benefit of specific immunotherapy seen in lymphoma

Pharma

Incyte: Monjuvi improves survival in patients with relapsed or refractory follicular lymphoma

January 10, 2025

StudyGraphics

#VisualAbstract Use of Certain Biologics or Disease Modifying Antirheumatic Drugs May Be Associated With Cancer Risk

December 5, 2024

Fine needle biopsy remains a reliable test for thyroid cancer diagnosis

Cervical conization may double risk of preterm birth

Anti-VEGF therapy for retinopathy of prematurity may be associated with pulmonary hypertension risk

Atrial fibrillation-specific management increases days alive and out of hospital

Artificial intelligence algorithm may increase atrial fibrillation detection rate in ambulatory setting

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports